drugset / Trial / NCT00048451

Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)

NCT00048451 ↗

Phase 3 Completed 68 enrolled Abbott
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to determine whether paricalcitol is safe and effective compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney disease.

Timeline

Start
2002-02
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Paricalcitol Other / unclassified — —